Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.56 |
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197589 | 0.92 | MET (0.53) | METKDR | |
| SCHEMBL12424217 | 0.87 | MET (0.62) | METKDRAXLMERTK | |
| SCHEMBL1794160 | 0.73 | MET (0.70) | METKDRAXL | |
| SCHEMBL29693453 | 0.72 | MET (1.00) | METKDRAXLMERTK | |
| SCHEMBL371651 | 0.72 | MET (1.00) | METKDRAXLMERTK | |
| SCHEMBL12424215 | 0.71 | NPC1 (0.34) | METAXL | |
| SCHEMBL5485300 | 0.71 | MET (0.45) | METKDRAXL | |
| SCHEMBL10245266 | 0.70 | MET (0.85) | METKDRAXLMERTK | |
| SCHEMBL29693555 | 0.70 | MET (0.88) | METKDRAXLMERTK | |
| SCHEMBL29693551 | 0.70 | MET (0.88) | METKDRAXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-1773826-A4 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1773826-A2 | C-MET MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014325-A2 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, KDR | MET 2/4885KDR 3/4885AXL 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.